Under 10% of patients who could benefit from obesity jabs including Wegovy are able to get them, caution the World Health Organization as it publishes its inaugural advice on the drugs.
Given over a billion people worldwide now obese, it is advocating for increased and just availability to this class of drugs.
According to estimates, over two billion are projected to be living with obesity by 2030 if no action is taken.
"The new guidance affirms that obesity is a lifelong illness that can be managed with thorough and continuous treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are significant hurdles to broad availability to the injections that can help people shift significant weight, says the organization.
Weight-Loss Drug Scarcity
Despite the present most optimistic outlook, the supply of such drugs could only cover approximately 100 million people – less than 10% of eligible patients, as stated by the health organization.
The advice urges governments and firms to expand access, through approaches such as voluntary licensing.
Exclusive production rights on the active ingredient – the main ingredient of a leading brand – is scheduled to end in several nations in 2026.
The Way Obesity Injections Work
These medications mimick a body's own hormone to delay gastric emptying, reduce hunger and increase the sense of being full so people eat less.
Individuals usually start to lose weight within a few weeks of beginning the weekly injections.
Research indicates people may put most of the weight back on within a year of discontinuing the medication, because their usual appetite come back.
Being carrying excess weight elevates your chance for experiencing health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and some cancers.
Obesity concerns people in all nations and was linked to 3.7 million fatalities worldwide in 2024, per the WHO.
